Skip to main content

TOP - November 2017, Vol 10, No 4

Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
By Phoebe Starr
Lung Cancer
TOP - November 2017, Vol 10, No 4

Chicago, IL—Alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, was called a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer (NSCLC), based on results of the phase 3 ALEX clinical trial, which were presented at the 2017 ASCO annual meeting.

Read More ›
Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer
By Wayne Kuznar
Gynecologic Cancers
TOP - November 2017, Vol 10, No 4
Chicago, IL—Oral cediranib, an investigational vascular endothelial growth factor (VEGF) inhibitor, in combination with a PARP inhibitor or with chemotherapy, shows survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to findings from 2 clinical trials presented at the 2017 ASCO annual meeting. Read More ›
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancers
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancers
By Wayne Kuznar
Breast Cancer
TOP - November 2017, Vol 10, No 4
OlympiAD provides proof of principle that breast cancers with defects in a specific DNA damage repair pathway are sensitive to a targeted therapy designed to exploit that defect, said Dr Robson. Read More ›
Abiraterone a Game-Changer in the Frontline Treatment of Metastatic Prostate Cancer
Abiraterone a Game-Changer in the Frontline Treatment of Metastatic Prostate Cancer
By David King
Prostate Cancer
TOP - November 2017, Vol 10, No 4

Adding abiraterone to standard initial treatment that includes androgen-deprivation therapy (ADT) increased survival and reduced mortality risk by 37% over 3 years versus standard of care in the STAMPEDE study of men with locally advanced or metastatic prostate cancer.

Read More ›
Pembrolizumab Makes Inroads in Sarcoma Subtypes
By Phoebe Starr
Immunotherapy
TOP - November 2017, Vol 10, No 4
Chicago, IL—The tumor types amenable to immunotherapy with the PD-1 inhibitor pembrolizumab (Keytruda) keep expanding and now include sarcoma, which has been difficult to treat. Read More ›
From The Editors - TOP November 2017
From the Editors
TOP - November 2017, Vol 10, No 4

Results from another clinical trial, ALEX, were also presented at the meeting, and led to alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, being hailed as a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer.

Read More ›
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
By Phoebe Starr
Breast Cancer
TOP - November 2017, Vol 10, No 4
CDK4/CDK6 inhibitors will most likely not have a role as monotherapy, said Ingrid Mayer, MD, Associate Professor of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, who discussed the study results. Read More ›
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma
By Lisa A. Raedler, PhD, RPh, Medical Writer
Drug Updates
TOP - November 2017, Vol 10, No 4
Marginal-zone lymphoma (MZL) is a malignancy that arises from B-lymphocytes in the marginal zone of lymphoid tissue. This slow-growing indolent B-cell lymphoma represents approximately 12% of all cases of non-Hodgkin lymphoma (NHL) in adults. Read More ›
Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma
By Chase Doyle
Multiple Myeloma
TOP - November 2017, Vol 10, No 4
According to the results of an open-label, phase 1b study presented at ASCO 2017, induction therapy with the KRd regimen was well-tolerated, and the overall safety profile was consistent with previous reports for KRd, with no additional toxicity observed with the addition of daratumumab. Read More ›
Noteworthy Numbers: Peripheral Neuropathy
Noteworthy Numbers
TOP - November 2017, Vol 10, No 4
Peripheral neuropathy is the result of damage to the peripheral nervous system, the complex network of nerves that transmits messages between the brain and other parts of the body. Such damage can cause impaired movement, loss of sensation in the arms and legs, numbness, tingling, and pain. Read More ›

Page 1 of 2